Kangxi Communications Technologies (Shanghai) Co., Ltd. v. Skyworks Solutions, Inc.

IPR2025-00373

Kangxi Communications Technologies has filed a petition for inter‑partes review of Skyworks' U.S. Patent 8,717,101 covering biasing circuits for RF power amplifiers. The challenger argues the claims are obvious over the Ishimaru publication and over Ishimaru combined with Harrison’s current‑mirror teaching, and opposes discretionary denial.

Jurisdiction
US PTAB
Case Number
IPR2025-00373
Decision Date
14 January 2025
Filing Date
14 January 2025

Detailed Summary

Kangxi Communications Technologies (Shanghai) Co., Ltd. petitioned the PTAB to institute an inter‑partes review of Skyworks Solutions, Inc.’s U.S. Patent 8,717,101, which claims a biasing architecture for RF power amplifiers that mitigates gain variation at startup. The petition asserts that claims 1‑2, 10‑11, 17‑18, and 20‑22 are unpatentable under 35 U.S.C. §103 as obvious over the Ishimaru publication, and further obvious when combined with the current‑mirror teachings of Linden T. Harrison. The petitioner also contends that a discretionary denial under the Fintiv factors or §325(d) would be improper because there is no parallel district‑court case and the related ITC investigation does not justify denial. The petition requests that the Board institute the IPR and cancel the challenged claims.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Kangxi Communications Technologies (Shanghai) Co., Ltd. vs Skyworks Solutions, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentPGR2026-00010

Wella Operations US LLCvsOlaplex, Inc.

Wella Operations seeks a post‑grant review of Olaplex’s ’225 patent, arguing the claims are too broad, lack enablement, written description, and are indefinite.

patentIPR2025-00989

Imperative Care, Inc.vsInari Medical, Inc. et al.

Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.

patentIPR2025-01036

Intel Corp. et al.vsGeneral Video, LLC

Intel and Dell seek to invalidate General Video's ’010 HDMI 3D patent, arguing that its claims are obvious over earlier HDMI standards and prior‑art patents (Tu, Suzuki, Yun, Lida). The petition requests the PTAB to institute an IPR and cancel the challenged claims.

patentIPR2025-00857

Apple Inc.vsAllani, Ferid

The PTAB granted institution of IPR for Apple against Ferid Allani's patent, focusing on web navigation claims. The Board found reasonable likelihood of unpatentability in several dependent claims but rejected it for the independent claims.

patentIPR2025-01006

Treasure Garden, Inc.vsATLeisure, LLC

ATLeisure, LLC seeks a discretionary denial of the IPR against its adjustable‑umbrella patent, arguing settled expectations, duplicate litigation, and prior art already considered by the USPTO.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call